MWManfred B Wischnewsky

Manfred B Wischnewsky

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Manfred B Wischnewsky has a total of 186 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Coexistence and outcome of coronary artery disease in Takotsubo syndrome

    by L Christian Napp, Victoria L Cammann, Milosz Jaguszewski, Konrad A Szawan, Manfred Wischnewsky, Sebastiano Gili, Maike Knorr, Susanne Heiner, Rodolfo Citro, Eduardo Bossone, et al.

    Aims: Takotsubo syndrome (TTS) is an acute heart failure syndrome, which shares many features with acute coronary syndrome (ACS). Although TTS was initially described with angiographically normal coronary arteries, smaller studies recently indicated a potential coexistence of coronary artery disease (CAD) in TTS patients. This study aimed to determine the coexistence, features, and prognostic role of CAD in a large cohort of patients with TTS. Methods and results: Coronary anatomy and CAD were studied in patients diagnosed with TTS. Inclusion criteria were compliance with the International Takotsubo Diagnostic Criteria for TTS, and availability of original coronary angiographies with ventriculography performed during the acute phase. Exclusion criteria were missing views, poor quality of angiography loops, and angiography without ventriculography. A total of 1016 TTS patients were studied. Of those, 23.0% had obstructive CAD, 41.2% had non-obstructive CAD, and 35.7% had angiographically normal coronary arteries. A total of 47 patients (4.6%) underwent percutaneous coronary intervention, and 3 patients had acute and 8 had chronic coronary artery occlusion concomitant with TTS, respectively. The presence of CAD was associated with increased incidence of shock, ventilation, and death from any cause. After adjusting for confounders, the presence of obstructive CAD was associated with mortality at 30 days. Takotsubo syndrome patients with obstructive CAD were at comparable risk for shock and death and nearly at twice the risk for ventilation compared to an age- and sex-matched ACS cohort. Conclusions: Coronary artery disease frequently coexists in TTS patients, presents with the whole spectrum of coronary pathology including acute coronary occlusion, and is associated with adverse outcome. Trial registration: ClinicalTrials.gov number: NCT01947621.


  • Reply

    by Ken Kato, Victoria L. Cammann, Manfred Wischnewsky, Jelena R. Ghadri, Christian Templin


  • Factors influencing the development of visceral metastasis of breast cancer: A retrospective multi-center study

    by Catharina Bartmann, Joachim Diessner, Maria Blettner, Sebastian Häusler, Wolfgang Janni, Rolf Kreienberg, Mathias Krockenberger, Lukas Schwentner, Roland Stein, Tanja Stüber, et al.


    • 1 August 2012
      • Vol. 24  (8) , 407-11

    Assessment of inflammatory response to transfemoral transcatheter aortic valve implantation compared to transapical and surgical procedures: a pilot study.

    by Barbara E Stähli, Jürg Grünenfelder, Stephan Jacobs, Volkmar Falk, Ulf Landmesser, Manfred B Wischnewsky, Thomas F Lüscher, Roberto Corti, Willibald Maier, Lukas A Altwegg

    Surgical aortic valve replacement (AVR) has been associated with systemic inflammatory reactions. Yet, the role of inflammation following transcatheter aortic valve implantation (TAVI) has not been fully elucidated. In a total of 40 patients evaluated by the 'heart team,' this retrospective study assessed levels of high-sensitive C-reactive protein (hs-CRP) and leukocyte counts following 'uneventful' AVR and TAVI. Four groups of matched patients were compared (AVR; transapical and transfemoral Edwards SAPIEN [TA ES and TF ES, respectively]; and transfemoral Medtronic CoreValve [TF CV]). A postprocedural increase of both hs-CRP levels and leukocyte counts was observed (P<.001) with peak levels 48 hours after the procedures. Comparing treatment groups, hs-CRP levels at 48 hours were significantly higher following AVR and TA ES compared to TF ES and TF CV (P<.04). Leukocyte counts at 48 hours were higher following TA ES compared to TF ES and TF CV (P<.03). Multivariate analysis incorporating both hs-CRP levels and leukocyte counts confirmed significant differences for all measurements over time (P<.001). Furthermore, the treatment group significantly influenced postprocedural hs-CRP levels and leukocyte counts (P<.001). Both AVR and TAVI evoke a postprocedural inflammatory response. Higher hs-CRP levels and leukocyte counts following AVR and apical TAVI suggest less inflammation following femoral procedures.


  • Up-Front Tandem High-Dose Chemotherapy Compared With Standard Chemotherapy With Doxorubicin and Paclitaxel in Metastatic Breast Cancer: Results of a Randomized Trial

    by Peter Schmid, Walter Schippinger, Thorsten Nitsch, Gerdt Huebner, Volker Heilmann, Wolfgang Schultze, Hubert Hausmaninger, Manfred Wischnewsky, Kurt Possinger

    Purpose: The role of high-dose chemotherapy (HDCT) in metastatic breast cancer remains controversial. Trials with late intensification HDCT have failed to show an advantage in overall survival. This study was initiated to compare up-front tandem HDCT and standard combination therapy in patients with metastatic breast cancer. Patients and Methods: Patients without prior chemotherapy for metastatic disease were randomly assigned to standard combination therapy with doxorubicin and paclitaxel (AT) or double HDCT with cyclophosphamide, mitoxantrone, and etoposide followed by peripheral-blood stem-cell transplantation. HDCT was repeated after 6 weeks. Patients were stratified by menopausal and hormone-receptor status. The primary objective was to compare complete response (CR) rates. Results: A total of 93 patients were enrolled onto the trial. Intent-to-treat CR rates for patients randomized to HDCT and AT were 12.5% and 11.1%, respectively (P = .84). Objective response rates were 66.7% for patients in the high-dose group and 64.4% for patients in the AT arm (P = .82). In an intent-to-treat analysis, there were no significant differences between the two treatments in median time to progression (HDCT, 11.1 months; AT, 10.6 months; P = .67), duration of response (HDCT, 13.9 months; AT, 14.3 months; P = .98), and overall survival (HDCT, 26.9 months; AT, 23.4 months; P = .60). HDCT was associated with significantly more myelosuppression, infection, diarrhea, stomatitis, and nausea and vomiting, whereas patients treated with AT developed more neurotoxicity. Conclusion: This trial failed to show a benefit for up-front tandem HDCT compared with standard combination therapy. HDCT was associated with more acute adverse effects.


  • Outcome analysis of 189 consecutive cancer patients referred to the intensive care unit as emergencies during a 2-year period

    by G. Maschmeyer, F.-L. Bertschat, K.T. Moesta, E. Häusler, T.K. Held, M. Nolte, K.-J. Osterziel, V. Papstein, M. Peters, G. Reich, et al.


  • Prediction of Response to Hormonal Treatment in Metastatic Breast Cancer

    by P. Schmid, M.B. Wischnewsky, O. Sezer, R. Böhm, K. Possinger

    Prediction of outcome and individualization of therapeutic strategies are challenging problems in oncology. Predictive parameters for response to hormonal treatment include the expression of hormone receptor, the extent and location of metastatic spread, disease-free interval, patient age, response to prior hormonal therapy, grading, and more recently, some molecular markers like the expression of HER-2/neu. The use of conventional statistics for prediction of response to hormonal treatment is limited by non-linearities and complex interactions between predictive factors. Modern computational mathematical models like artificial neural networks, entropy-based inductive algorithms or χ2 interaction detection algorithms can describe these interactions and generate classification models and decision structures. They can be used to predict the clinical outcome for individual patients. In contrast to conventional methods, the level of confidence for the predictions can reach 90% and more. This might be an important step towards further individualization of therapeutic strategies.


    • 9 June 2001
      • Vol. 21, 1301-5

    Weekly intravenous recombinant humanized anti-P185HER2 monoclonal antibody (herceptin) plus docetaxel in patients with metastatic breast cancer: a pilot study.

    by H Meden, A Beneke, T Hesse, I Novophashenny, M Wischnewsky

    In patients with HER2-positive metastatic breast cancer (MBC), combined treatment of herceptin (H) and chemotherapy (CT) improves time to progression, response rates and survival compared with CT alone. We evaluated the safety and efficacy of weekly Docetaxel combined with weekly H as treatment in HER2 overexpressing MBC. Preliminary toxicity data from 12 patients and 76 cycles of D and 80 cycles of H were analysed. No G3/4 toxicity was observed. The most frequent non-hematologic toxicities were fatigue (2 patients G2, 2 patients G1), dyspepsia (1 patients G2, 3 patients G1), diarrhea (1 patient G2, 3 patients G1), and nausea (1 patient G2, 3 patients G1). Six partial responses have been observed in 12 patients (ORR 50%). The combination of weekly Docetaxel and Herceptin is well tolerated with significant anti-tumor activity.


    • 1 January 2000
      • Vol. 77, 379-82

    [Quality assurance by evidence-based evaluation of treatment outcome (exemplified by dentistry)].

    by M Kus, W Walther, M B Wischnewsky

  • Open Access

    Audit and quality control in angioplasty in Europe: procedural results of the AQUA Study 1997; assessment of 250 randomly selected coronary interventions performed in 25 centres of five European Countries

    by W. Maier, M.F. Enderlin, T. Bonzel, N. Danchin, G. Heyndrickx, V. Mühlberger, K.L. Neuhaus, F. Piscione, N. Reifart, J. Antoni, et al.

    Aims Percutaneous transluminal coronary angioplasty (PTCA) has become the most widely used major intervention in western medicine. However, there is